After listening to Ouyang Feifei's explanation, Luo Ziling finally understood the gist.
It turns out that Ouyang Feifei had been suggesting a merger and restructuring between Lingyun Pharmaceutical and Northern Pharmaceuticals to form a single pharmaceutical company.
After restructuring, the business can be divided into two parts, one for Western medicine and one for traditional medicine. However, she worried that the traditional medicine side had too few products, which would hinder business growth.
The few medicines that Luo Ziling has developed could be considered as adding the finishing touch, making the financial statements look good, and showing decent growth in various indicators. But if these products alone were to support a listed company, they might seem too thin.
The products in the Western pharmaceutical industry are rich and very profitable.
